| Quantity | 1 mg, 5 mg, 10 mg | 5 mg, 10 mg, 25 mg | 500 µ, g, 1 mg, 5 mg, 10 mg | 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 5 mg, 10 mg |
| Description | RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2] | Endomorphin 1 acetate, a high affinity, highly selective agonist of the µ-opioid receptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties[1][2][4] | Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor | Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis[1][2][3][4][5][6]... Read More | S7 is an IL-6 receptor antagonist and inhibits the binding between IL-6 and IL-6R. S7 can inhibit angiogenesis and tumor growth[1] |